Global Pemphigus Vulgaris Treatment Market - 2024-2031

Global Pemphigus Vulgaris Treatment Market - 2024-2031

The global pemphigus vulgaris treatment market reached US$ 473.4 million in 2023 and is expected to reach US$ 896.1 million by 2031 growing with a CAGR of 8.3% during the forecast period 2024-2031.

Pemphigus vulgaris is a rare group of autoimmune diseases. It causes blisters on the skin and mucous membranes throughout the body. It can affect the mouth, nose, throat, eyes, and genitals. As the most prevalent type of pemphigus, its onset typically occurs between ages 40 and 60, affecting both genders equally. It can be very serious, but treatment can help to control it.

The main treatments available in the market for treating pemphigus vulgaris treatment are steroid tablets and other medicines such as azathioprine, methotrexate, and rituximab. Systemic corticosteroid therapy is another form of treatment and is recommended at a dose of 1.0–1.5 mg/kg/day of prednisolone equivalent, depending on disease severity, the patient a possible comorbidities. Some of the new treatments available in the market for the treatment of pemphigus vulgaris treatment are veltuzumab, ocrelizumab, and obinutuzumab.

Market Dynamics: Drivers

Increasing incidence and prevalence of pemphigus vulgaris disease

The demand for the global vein finders market is driven by multiple factors. One of the primary factors is the increasing incidence and prevalence of pemphigus vulgaris disease.

Pemphigus vulgaris is a rare and potentially life-threatening autoimmune disorder that causes severe blistering of the skin and mucous membranes. According to an NCBI research publication in August 2023, the incidence of PV ranged from 0.098 to 5 patients per 100,000 people. The prevalence of PV ranged from 0.38 to 30 per 100,000 people.

Moreover, key players in the industry focus on the treatment for pemphigus vulgaris, and the rising number of clinical trials, innovative product launches, & approvals would drive this market growth. For instance, in May 2023, Topas launched the Phase IIa trial of celiac disease therapy. The placebo-controlled, double-blind, randomized, multicenter study will assess the tolerability, safety, and pharmacodynamic effects of two TPM502 administrations in dose-escalating cohorts. The Phase IIa study has been launched based on the positive clinical data from the Phase I study of TPM203 in pemphigus vulgaris treatment patients.

Similarly, in July 2022, Almirall launched a new call to find innovative therapies for skin diseases. An open innovation platform for proposals to establish collaborations in dermatological research. This year’s edition aims to find new partnership opportunities for assets in preclinical or clinical development stages that can become new treatments for skin diseases.

Restraints

Factors such as the high cost of treatment, adverse effects associated with the medication, stringent regulatory guidelines, and lack of awareness & Diagnosis are expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global pemphigus vulgaris treatment is segmented based on treatment type, route of administration, end-user, and region.

The biological therapies segment accounted for approximately 43.3% of the global pemphigus vulgaris treatment share

The biological therapies segment is expected to hold the largest market share over the forecast period owing to biologics excelling in treating pemphigus vulgaris treatment due to their targeted effectiveness, addressing disease-related molecules precisely. With minimal side effects, they surpass traditional therapies. Cost-wise, biologics prove economical, utilizing living cells or natural sources, and reducing production and distribution expenses.

Moreover, their lower dosage requirement further cuts treatment costs. Individualized treatment is another advantage, as biologics can be tailored to target specific molecules, enhancing efficacy. Advancements in both disease understanding and biotechnology have yielded advanced biologics, solidifying their status as the favored choice for pemphigus vulgaris treatment furthermore, the rise in European approvals.

According to Dovepress research publication in October 2022, anti-CD20 monoclonal antibody rituximab is an approved adjuvant treatment, in combination with oral corticosteroids, for patients with pemphigus vulgaris, a severe and potentially life-threatening autoimmune blistering skin disorder. Updated approaches to the management of pemphigus vulgaris support rituximab as a first-line adjuvant treatment to induce remission early in the course of the disease.

Similarly, in Frontiers' publication in February 2022, biological thiol substances such as cysteine and glutathione have been shown to induce acantholysis in human skin fragments under certain experimental conditions. In vitro experiments subsequently demonstrated that thiol drugs (d-penicillamine, captopril, theobromine, and piroxicam) induce acantholytic splitting in human skin fragments or skin cultures in the absence of pemphigus antibodies.

From the same source, more recently, advances in our understanding of the pathogenesis of pemphigus and the biological mechanisms of therapeutics have led to a paradigm shift in the treatment of this disease, from blanket immunosuppression towards a more targeted restriction of autoimmunity.

Moreover, the rising number of clinical trials would propel this segment's growth. For instance, In January 2023, Dr Reddy completed clinical studies of its rituximab biosimilar for filing in the US, and Europe.

The full set of clinical studies of Dr Reddy’s Laboratories Ltd (Dr Reddy’s) pro. According to the company, DRL_RI is being developed as a biosimilar of rituximab, a cluster of differentiation 20 (CD20) directed cytolytic antibodies for approval. Including treatment of adult patients with pemphigus vulgaris treatment and other autoimmune disorders.

Geographical Analysis

North America accounted for approximately 41.2% of the global pemphigus vulgaris market share

North America region is expected to hold the largest market share over the forecast period owing to the increasing incidence & prevalence of pemphigus vulgaris, well-advanced healthcare infrastructure, and rising awareness among individuals would propel this market growth in this region.

Pemphigus vulgaris (PV) is a rare autoimmune disorder of the skin and mucous membranes that causes painful sores and blisters on the skin and mouth. According to PAN Foundation in January 2023, about three in every 100,000 people in the U.S. are living with pemphigus vulgaris. Every year, PV incidence varies from 0.1-0.5 cases per 100,000 population with a higher prevalence in Europe and the United States of America.

Moreover, government initiatives such as financial support and key strategies such as partnerships & collaborations would drive this market growth in this region. For instance, in January 2023, the PAN Foundation opened a new financial assistance program for people living with pemphigus vulgaris, providing up to $6,600 per year for eligible patients. 

We are proud to launch this new fund, offering support to those affected by this rare and chronic disease. Pemphigus vulgaris can be life-threatening if left untreated, and we hope that PAN’s financial support will make sure more people will be able to access the care they need.

Also, in August 2023, Cabaletta Bio and WuXi Advanced Therapies announced the expansion of the GMP Manufacturing agreement to include CABA-201. One of the strategies is the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis.

Market Segmentation

By Treatment Type
• Corticosteroid
• Immunosuppressants
• Biological Therapies
• Intravenous Immunoglobulin (IVIG) Therapy
• Others

By Route of Administration
• Oral
• Parenteral
• Subcutaneous

By End User
• Hospitals & Clinics
• Specialty Dermatology Clinics
• Research & Academic Laboratories

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the pemphigus vulgaris treatment market include F. Hoffmann-La Roche Ltd, Pfizer Inc, Teva Pharmaceutical Industries, Novartis AG, Sanofi, AbbVie Inc, AstraZeneca, Zydus Group, GSK Plc and Syntimmune among others.

Key Developments

 In December 2023, argenx SE announced topline results from the address study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with pemphigus vulgaris (PV) and pemphigus foliaceus (PF).

 In October 2022, IASO Biotherapeutics announced that the companies entered into an agreement under which Cabaletta obtained from IASO Bio an exclusive, worldwide license to develop, manufacture, and commercialize a clinically validated fully human CD19 binder for use in a product that is designed to modify T cells in the treatment of autoimmune diseases.

Why Purchase the Report?
• To visualize the global pemphigus vulgaris treatment market segmentation based on treatment type, route of administration, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of pemphigus vulgaris treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global pemphigus vulgaris treatment market report would provide approximately 62 tables, 58 figures, and 182 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies